Form D · Pharmaceuticals
Tremeau Pharmaceuticals, Inc.
Cambridge, MA · CIK 0001722110
Offering snapshot reported Feb 15, 2018 · SEC filing
- Reported sold
- $5.2M Offering amount: $5.2M
- Investors reported
- 59 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Oct 17, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 15, 2018 | Initial | $5,196,001 | No comparison | 59 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-305704
Offering and sales amounts consist of (i) common stock investments of $4,186,001 and (ii) convertible note investments (all of which have converted to common stock) with an aggregate principal amount of $1,010,000.
Source: Form D, filed Feb 15, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Corrigan | Executive |
| Benjamin Enerson | Executive |
| Bradford C. Sippy | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
One Broadway 14 Th Floor
Cambridge, MA, 02142
Cambridge, MA, 02142